Lyell Immunopharma stock hits 52-week low at $0.48

Lyell Immunopharma Inc. (LYEL) stock has reached a new 52-week low, trading at $0.48, with a market capitalization of $142.3 million. This latest price point underscores a significant downturn for the biotechnology company, which specializes in cancer treatments. According to InvestingPro analysis, the stock appears undervalued at current levels. Over the past year, Lyell Immunopharma has seen its stock value decrease by a staggering 76.6%, reflecting investor concerns and a challenging market environment for the sector. Despite maintaining a strong liquidity position with a current ratio of 7.06 and more cash than debt, the company is quickly burning through its resources. The stock’s negative beta of -0.42 indicates it often moves contrary to broader market trends. InvestingPro subscribers have access to 12 additional key insights about LYEL’s financial health and market position.

In other recent news, Lyell Immunopharma has announced the closure of its West Hills manufacturing facility, resulting in the reduction of approximately 73 jobs. This decision follows the successful transfer of technology to its Bothell, Washington facility, which has received FDA clearance to manufacture IMPT-314 for clinical trials. The closure is expected to incur costs between $3.0 million and $4.0 million, primarily related to severance and associated expenses. Lyell Immunopharma has also maintained its financial guidance for 2025, projecting a net cash use between $175 million and $185 million, extending its cash runway into 2027.

Additionally, H.C. Wainwright has reiterated a Neutral rating on Lyell Immunopharma’s stock, highlighting the ongoing development of its IMPT-314 candidate for treating relapsed/refractory large B-cell lymphoma. The analysts are particularly interested in upcoming data from the Phase 1/2 trials, expected in mid-2025, and have expressed caution due to the competitive landscape of CAR-T therapies.

Moreover, Lyell Immunopharma has been notified by Nasdaq of non-compliance with the minimum bid price requirement, as its stock has closed below $1.00 for 33 consecutive business days. The company has until July 22, 2025, to regain compliance or risk potential delisting. Lyell is considering various measures, including a reverse stock split, to address the issue, although there is no guarantee of success in meeting Nasdaq’s listing criteria.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.